Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004202 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy, Radiation Therapy, and RSR13 in Treating Patients With Stage III Non-small Cell Lung Cancer
A Phase 2 study, sponsored by Spectrum Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00004202: Completed Phase 2 study, sponsored by Spectrum Pharmaceuticals.
NCT00004202 is a Phase 2 study that has completed, run by Spectrum Pharmaceuticals. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004202, a Phase 2 study, has completed, sponsored by Spectrum Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as RSR13 may make tumor cells more sensitive to radiation therapy. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy, radiation therapy, and RSR13 in treating patients who have stage III non-small cell lung cancer that cannot be removed by surgery.
Interventions
- DRUG carboplatin
- DRUG paclitaxel
- RADIATION radiation therapy
- DRUG chemotherapy
- DRUG efaproxiral
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-10 |
| Est. Completion | 2003-01 |
| Phase | Phase 2 |
What the finished NCT00004202 record still lists
NCT00004202 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 5 interventions - of which carboplatin is the first listed.
NCT00004202 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00004202 about?
NCT00004202 is a clinical study titled "Combination Chemotherapy, Radiation Therapy, and RSR13 in Treating Patients With Stage III Non-small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as RSR13 may make tumor cells more sensitive to radiation therapy. PURPOSE: Phase II trial to study the...
What is the current status of trial NCT00004202?
This trial is currently completed. It is a Phase 2 study. The study started on 1998-10. Estimated completion is 2003-01.
What interventions are being tested in trial NCT00004202?
The interventions under investigation include: carboplatin (DRUG), paclitaxel (DRUG), radiation therapy (RADIATION), chemotherapy (DRUG), efaproxiral (DRUG).
Who is sponsoring clinical trial NCT00004202?
This trial is sponsored by Spectrum Pharmaceuticals, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia